What is PBLA stock price today?

PBLA (Panbela Therapeutics Inc) stock is trading at $0.00 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is PBLA stock going up or down today?

PBLA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PBLA stock now?

The decision to buy PBLA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PBLA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PBLA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PBLA stock overvalued or undervalued?

Use our DCF valuation calculator to determine if PBLA is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is PBLA's P/E ratio?

P/E ratio data for PBLA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is PBLA's market cap?

PBLA (Panbela Therapeutics Inc) has a market capitalization of $0.00 billion, making it a small-cap stock.

What is PBLA's price to book ratio?

PBLA trades at a price-to-book (P/B) ratio of 3.22, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does PBLA pay dividends?

PBLA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PBLA's dividend yield?

PBLA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PBLA stock a good long-term investment?

PBLA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PBLA's revenue growth rate?

Revenue growth data for PBLA is available on our dashboard with detailed financial statement analysis.

Profitability metrics for PBLA are available on our dashboard with complete income statement analysis.

What are the risks of investing in PBLA?

Key risks for PBLA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PBLA compare to its competitors?

Compare PBLA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PBLA's performance and positioning.

What is PBLA's stock price target for 2026?

Our AI model provides price targets for PBLA based on fundamental analysis: Bull case $0.00 (+30%), Base case $0.00 (+15%), Bear case $0.00 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about PBLA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PBLA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PBLA's next earnings report?

PBLA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PBLA - Panbela Therapeutics Inc

NYSE * Health Care * Biotechnology

$0.00

+$0.00 (+0.00%)

About Panbela Therapeutics Inc

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

PBLA Key Statistics

Market Cap

$0.00M

P/B Ratio

3.22

EPS

$-34.51

Employees

How PBLA Compares to Peers

PBLA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PBLA(This stock)	$970.00	N/A	0%	0.0%	-
AMGNAmgen Inc	$191.53B	24.9	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.2	-0%	0.1%	vs BIIB

Panbela Therapeutics Inc Company Information

Headquarters: Minnesota; U.S.A
Website: www.panbela.com
Sector: Health Care
Industry: Biotechnology

About Panbela Therapeutics Inc

PBLA Key Statistics

How PBLA Compares to Peers

Panbela Therapeutics Inc Company Information

Upcoming Events for PBLA